RecruitingPhase 2NCT05465174
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Studying Craniopharyngioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Sabine Mueller, MD, PhD, MAS, DOUniversity of California, San Francisco
- Intervention
- Tovorafenib(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 1-39 years · All sexes
- Timeline
- 2022 – 2028
Study locations (19)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Rady Children's Hospital/University of California, San Diego, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Florida, Gainesville, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
- John Hopkins University, Baltimore, Maryland, United States
- Dana-Farber/Boston Children's Harvard Medical School, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Children's Minnesota, Minneapolis, Minnesota, United States
- St. Louis Children's Hospital Washington University, St Louis, Missouri, United States
- NYU Langone Health, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- +4 more locations on ClinicalTrials.gov
Collaborators
Day One Biopharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05465174 on ClinicalTrials.govOther trials for Craniopharyngioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07177482ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma PatientsDeling Li
- RECRUITINGNCT06801756Craniopharyngioma and PregnanciesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT05525273Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary CraniopharyngiomaEva Marie Erfurth, MD, PhD
- ENROLLING BY INVITATIONNCT03610906Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical TherapyUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGPHASE2NCT03224767Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaAlliance for Clinical Trials in Oncology
- ACTIVE NOT RECRUITINGPHASE2NCT02792582A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical ResectionSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT01419067A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical ResectionSt. Jude Children's Research Hospital